OMA Guidelines Bundle

Obesity Pharmacotherapy - OMA Obesity Algorithm 2023

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 29 of 29

Abbreviations ALA, alpha lipoic acid; BID, two times a day; BMI, body mass index; CA, cancer; CGRP, calcitonin gene-related peptide receptor; CLA, conjugated linoleic acid; CVD, cardiovascular disease; DEA, Drug Enforcement Administration; DPP4, dipeptidyl peptidase-4; EGCG, epigallocatechin gallate; FDA, Food and Drug Administration; FH, familial hypercholesterolemia; GIP, glucose-dependent insulinotropic peptid; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HAART, highly active antiretroviral therapies; HCG, human chorionic gonadotropin; HDL, high- density lipoprotein; HIV, human immunodeficiency virus; h/o, history of; LEPR, leptin receptor; MAOI, monoamine oxidase inhibitor; MEN, multiple endocrine neoplasia; mTOR, mammalian target of rapamycin; NASH, nonalcoholic steatohepatitis; NSAIDs, non-steroidal anti-inflammatory drugs; ORC, obesity related complication(s); OTC, over-the-counter; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin; PPA, phenylpropanolamine; TMAO, trimethylamine N-oxide; USP, United States Pharmacopeia; VUS, variant of uncertain significance Source Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, Ng J, Golden A, Davisson L, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2023. https://obesitymedicine.org/obesity-algorithm. (Accessed = January 2023) Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. 1258 Upsala Rd Sanford, FL 32771 TEL: 407.878.7606 FAX: 407.878.7611 Copyright © 2023 All rights reserved Obesity Medicine Association 7173 S. Havana St #600–130 Centennial, CO 80112 TEL: 303.770.2526 OMAOBEPS03233

Articles in this issue

Links on this page

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - OMA Obesity Algorithm 2023